Historical control data have been shown to be valuable in the interpretation and evaluation of results from rodent carcinogenicity studies. Standardization of terminology and histopatholog y procedures is a prerequisite for meaningful comparison of control data across studies and analysis of potential carcinogenic effects. Standardization is particularly critical for the construction of a database that includes incidence data from different studies evaluated by pathologists in different laboratories. Standardized nomenclature and diagnostic criteria have been established for neoplasms and proliferative lesions. Efforts of the National Toxicology Program, the Society of Toxicologic Pathology (STP), and the Registry of Industrial Toxicology Animal-data (RITA) have led to a harmonized pathology nomenclature for the rat and the mouse. This nomenclature with detailed descriptions of lesions is available in publications by the STP and International Agency for Research on Cancer (IARC). A listing of these terms is available on the World Wide Web. Utilizing the model established by RITA and working with the International Life Sciences Institute (ILSI), companies with laboratories in North America formed a working group in 1994 to establish and maintain a database of neoplastic and proliferative lesions from control animals in carcinogenicity studies. The rationale for developmen t of the North American Control Animal Database (NACAD), the factors that in uence tumor incidence, operation of the database, and the bene ts to be realized by using a standardized approach are discussed.
INTRODUCTION
In the development of a potential new drug or chemical, chronic toxicity and carcinogenicity studies are commonly performed to identify tumorigenicity in rodents and to assess the potential for human risk. In the evaluation of data from these studies, the incidences of pathological changes in compound-exposed groups are compared to those in the control groups and statistical analysis applied to identify compound-related effects. Although comparisons with concurrent controls from the same study are most appropriate for interpretation of incidences of neoplasms, historical control animal data can provide valuable information that is not available from concurrent controls (4, 10) . For historical control data to be reliable and useful, nomenclature, diagnostic criteria, trimming guidelines, and data entry elds and procedures must be standardized.
In a survey of toxicologists and toxicologic pathologists conducted within the United States, Europe, and Japan, respondents indicated the need for a historical control animal database that was regularly updated (6) . The North American Control Animal Database (NACAD) developed from the vision and need for a shared centralized control animal database of proliferative and neoplastic lesions in North America. The North American Control Animal Database was initiated in 1994 by the International Life Sciences Institute (ILSI) to develop a standardized, readily searchable, computerized database for incidences of neoplastic and selected nonneoplastic lesions in control rodents. Since initiation, a working group of toxicologic pathologists representing pharmaceutical, chemical, and food industries have collaborated with ILSI and the Fraunhofer Institute of Toxicology and Aerosol Research in Hannover, Germany, to establish and build the North American Control Animal Database. Fraunhofer Institute provides the operational base for NACAD and the Registry of Industrial Toxicology Animal-data (RITA).
The Value of Historical Control Data
Although the concurrent control is the best comparator in toxicity studies, limitations may arise when comparing concurrent control animal data to treated groups. Examples include assessment of borderline increases in tumor incidence in treated animals relative to concurrent controls and evaluation of the incidences of rare tumors. In such instances, access to accurate standardized historical control data may prove valuable in interpretation and assessment of results in carcinogenicity studies.
Computerized historical databases, particularly those that are Web-based such as RITA and NACAD, allow for readily available access to control data and serve as a comprehensive repository of ancillary study data, such as food consumption/feeding conditions, which may impact overall spontaneous tumor incidence. In addition to obtaining incidences of spontaneous neoplastic or proliferative lesions, historical control databases allow for assessment of survival rates of control animals and lesion development over time in different animal strains and stocks.
Standardized Nomenclature and Diagnostic Criteria
Efforts to standardize terminology for neoplastic and proliferative lesions started in the 1980s. The Society of Toxicologic Pathology initiated the Standardized System of Nomenclature and Diagnostic Criteria (SSNDC) Guides for Toxicologic Pathology. This effort was based on a series of organ system subcommittees with expert representation and was led by a coordinating committee of individuals from industry and government. The coordinating committee summarized the critical need for standardization in the introduction to the SSNDC Guides. The American Registry of Pathology at the Armed Forces Institute of Pathology publishes the Guides. A similar standardization effort began in Europe with the formation of RITA and the development of systematized nomenclature with diagnostic criteria for use in their database. The nomenclature and criteria developed by RITA were published by the International Agency for Research on Cancer (IARC) under the title "International Classi cation of Rodent Tumours, Part 1, Rat" following review by an independent editorial board. Although these started as separate initiatives, each had representatives from Europe, Japan, and the United States, thus providing a foundation for international harmonization.
The working group of NACAD devoted several months to critical review of the nomenclature proposed by the STP Guides and the IARC fascicles and recommended several changes to improve consistency of terminology. Another independent review by an international joint committee coordinated by ILSI and STP made a set of nal recommendations for the rat, incorporating many of the changes proposed by NACAD [STP home page: http://www.toxpath.org]. Publication of the recommended nomenclature for the mouse will be forthcoming. RITA and NACAD have adopted these recommendations for use in their databases. The nomenclature in use is based on literature with some adaptation for use in practical toxicologic pathology. Organ systems are categorized by organs and subtopographies. Lesions that are speci c for an organ are listed under the organ name according to their site of origin and histogenesis, for example, mammary gland, adenoma. Lesions can be further subclassi ed by describing a growth pattern or cell type using lesion modiers, for example, alveolar; cystic; papillary; tubular. For those neoplasms that can potentially occur in any organ because of the cellular origin, a separate class of "generally used preferred terms" is available. Examples includebroma, neuroendocrine neoplasms, hemangiosarcoma, and others.
Even more critical than standardized terminology is the standardization of diagnostic criteria used to characterize a lesion. Questions from regulatory agencies often relate to uncertainty about the morphologic characterization of the terminology being used. RITA developed nomenclature manuscripts which provide concise reviews of pertinent characteristics including histogenesis, diagnostic features (staining, size, growth patterns, etc) and differential features to aid in distinguishing hyperplastic from neoplastic lesions and benign from malignant neoplasms. These manuscripts form the basis for the IARC publications as noted previously and are available electronically as Registry Nomenclature Information System (RENI). NACAD has access to these manuscripts and member company pathologists use these as a guide. For any newly identi ed proliferative lesion, a manuscript is added to the system to provide the most current information.
The primary purpose of the database is to provide information on the incidence of neoplastic and proliferative lesions, because these are the crucial ndings for analysis in carcinogenicity assessments. In addition to these lesions, NACAD members decided to track several nonneoplastic lesions that may be unusual or for which there is no reliable historical control data. Some examples of this type of lesion include hypertrophic focus in the salivary gland, cystic degeneration in the liver, and keratinizing squamous cyst in the lung.
Factors Affecting Spontaneous Tumor Incidence
Factors that have been reported to have an in uence on tumor rates generally fall into two categories-study design and histological procedures. Study design factors include the strain of animal, the source, the age and sex of the animal, the environmental conditions (caging, lighting, bedding, etc), the microbial status and dietary source and amount fed. The histological factors include tissues selected, orientation in trimming, number of sections surveyed, staining procedures and diagnostic criteria applied by the pathologist. An extensive discussion of these variables can be found in a review by Haseman et al (4) . Some of the key environmental in uences include lighting and numbers of animals per cage. One of the most important experimental variables is age, as differences in tumor rates may simply re ect the greater survival of one group over another. There is considerable information on how the type of diet and the amount consumed can in uence tumor incidence (5, 8, 9) . Information on many of the study design factors is captured in the RITA and NACAD databases, thus providing a means to examine their potential effects on tumor incidence.
The second major category of factors includes methods for tissue preparation and histopathologic evaluation. A standard dissection is necessary to insure that all animals are examined in a similar manner for the detection of gross lesions and collection of all required organs. Using set trimming procedures prevents bias that might be introduced by producing variable numbers of sections or variable orientation. Not surprisingly, numbers of tumors can increase with multiple sections or changes in orientation (2, 3) , so all groups within a carcinogenicity study should have tissues prepared in the same way. The RITA working group initiated a thorough review of trimming approaches and published the results of their efforts-all member companies use these guidelines (1) . The NACAD working group reviewed the approach for each organ and adopted these guidelines with a few minor modi cations (Table 1) . When a study is entered into the database, one of the questions to be answered is whether or not a sponsor utilized the trimming guidelines. Staining procedures should also be as consistent as possible with animals from each group processed concurrently such that any variations in staining will be spread across all groups.
Finally and most importantly, the diagnostic criteria that the study pathologist utilizes must be standardized and applied consistently. This is best accomplished by having the same pathologist evaluate all the slides on a study. Because of the qualitative nature of histopathologic evaluation, there will be occasional variation in applying the diagnostic criteria by the same pathologist (diagnostic drift) and among pathologists. Subjecting the results of each study to a peer review by another experienced pathologist provides the appropriate quality control. This approach has been utilized successfully for many years by the NTP and has become an accepted industry practice. RITA subjects all studies to a peer review by a single pathologist. NACAD provides for a complete peer review of all lesions captured in the database by the sponsoring company prior to entry into the database. This assures that diagnostic criteria are applied consistently so that information across studies can be reliably compared. Periodic meetings of pathologists from member companies (panel meetings) provide another opportunity to discuss unusual or problematic cases to further re ne the criteria utilized in making nal diagnoses. 
The Design of the NACAD System
To maintain a standardized and reliable source of historical control data, control data from studies using established standardized nomenclature and diagnostic criteria and tissue trimming procedures continue to be added to NACAD by member companies. Active participation in NACAD increases the number of studies in the database, which will in turn increase the value of historical control data.
The NACAD system is tailored closely to the European RITA system (7) . Specially designed and user-friendly PC software, Regina3, is used to enter study data and is applicable for DOS, Windows 3.1x, Windows 95/98/ME or Windows NT systems. Study data is entered either by the NACAD participating company or by an independent pathology consulting rm. Overview of NACAD Data Entry (Figure 1) Study Initialization: The user enters basic information regarding the study such as the name of the study, the animal species used (mouse/rat), number of control study groups, number of males/female in each group and animal numbering scheme.
Study-Related Data (General and Group Data Entry)
These modules allow the user to enter pertinent study parameters, which may impact spontaneous tumor incidence. Parameters recorded include animal room conditions (eg, animal room size, temperature, humidity, air exchange rate, light/dark sequence, mean light intensity), drinking water conditions (eg, water supplier, drinking system type, water pH, and water conditioning), housing requirements (cage type, number of animals/cage, bedding material), diet type, and composition and food consumption.
Protocol Organ Data
To calculate lesion incidences, entry of protocol organs (tissue list) is required for the database. Each protocol tissue is individually listed and also entered are total numbers of samples for each tissue, plane of sectioning performed at trimming, and trimming guideline speci cations. The NACAD system can accommodate various tissue blocking schemes commonly utilized by most companies. Although not required, entry of blocking schemes is encouraged as the NACAD system automatically creates individual microscopic slide numbers from the block list. The NACAD system has a copy function that will allow the user to copy the same blocking scheme to a new study.
Histopathology Data
The selection of a standard nomenclature for NACAD data entry was determined following numerous discussions by NACAD working group members and is based on diagnostic criteria used in the Society of Toxicologic Pathologists (STP) Guides and the World Health Organization (WHO)/International Agency for Research on Cancer (IARC) fascicles. Speci c hyperplastic and all neoplastic lesions are included in the database. NACAD also currently includes some nonproliferative lesions (hepatic cystic degeneration). Each diagnosis included in the database is assigned a preferred diagnostic term. Synonyms for preferred terms are also stored in the system lexicon. The diagnosis may be expanded by one or more modi ers that more precisely describe lesion character (ie, malignancy, metastases), lesion multiplicity, and the unilateral or bilateral involvement in paired organs. Additional data such microscopic slide numbers and free text for each nding can be entered.
Prior to data entry, all tracked histopathology ndings for each control animal are peer-reviewed by the submitting company's pathologist(s). Questionable or uncommon histopathological ndings are presented to the NACAD working group at periodic panel meetings. Utilizing a multiheaded microscope, participating pathologists discuss and review slides of representative lesions, con rm diagnoses, and review established diagnostic criteria.
Data Acquisition and Validation Procedure in the NACAD System
Following data entry, data are reviewed by the submitting company and are transferred to the Fraunhofer Institute of Toxicology and Aerosol Research in Hannover, Germany, the location of the database. The data is imported in a le using a PDE (Pathology Data Exchange) format, speci cally designed for the NACAD system. Although currently not in routine use by NACAD participating companies, the NACAD system permits electronic data transfer to the Fraunhofer Institute.
The study data are stored in a preliminary database and a data check program is utilized to check for errors and ensure completeness of the data. Fraunhofer Institute releases a report containing all entered study data to the submitting company for complete review and signature for validation. Errors detected by the data check program or following company review are corrected either by the company responsible or at Fraunhofer in consultation with the submitting company. Following review and resolution of errors, the validated study report is signed by the company representative and forwarded back to Fraunhofer for archiving. The study data are then maintained in the database and available for generation of speci c reports.
